Increased Ebola funding contributes to declines in other disease research

Excessive Ebola funding contributes to declines in other disease research | Courtesy of
The eighth annual G-FINDER report shows that the worldwide investment funding Ebola research has resulted in a decline in efforts to create vaccines, drugs and diagnostics for other diseases that kill over 6 million people worldwide each year.

The report states that $3.4 billion was provided for "neglected disease" research and drug development, including Ebola in 2014. New investments for Ebola alone increased because of the 2014 West African Ebola outbreak by $150 million.

In contrast, investments for other neglected diseases have not increased or have declined by $14 million, amounting to a 0.4 percent reduction.

A sum of $165 million in funds has been spent on Ebola research and development in 2014, exceeding the funding for any neglected disease other than malaria, HIV/AIDS, tuberculosis, and diarrheal diseases. The majority of these investments are from the U.S. government, which contributed $101 million, or 86 percent, of public funding.

"This represents significant new investment in Ebola R&D, which was mobilized very quickly," Nick Chapman, the co-author of the report and the director of research at Policy Cures, said. "The challenge will be to make sure that this attention and funding is maintained as the epidemic subsides, to ensure that these products complete development."

Organizations in this story

PATH: Global Health Technologies Coalition 2201 Westlake Ave Seattle, WA - 98121

Get notified the next time we write about PATH: Global Health Technologies Coalition!